← Back to guidelines
Cardiology79 papers

Inclusion body fibromatosis

Last edited: 4/15/2026

Overview

Inclusion body fibromatosis, more commonly referred to as inclusion body myositis (IBM), is a rare inflammatory-degenerative myopathy predominantly affecting elderly individuals over 50 years old 1. It often presents diagnostic challenges due to frequent misdiagnosis as polymyositis or motor neuron disease 1.

Diagnosis

  • Clinical Presentation: Muscle weakness, particularly in quadriceps, finger flexors, and wrist extensors 1.
  • Electromyography (EMG): Characteristic findings include fibrillation potentials and spontaneous muscle fiber necrosis 1.
  • Muscle Biopsy: Essential for diagnosis, showing inflammatory infiltrates and characteristic inclusion bodies 1.
  • Differential Diagnosis: Rule out polymyositis, amyotrophic lateral sclerosis, and other inflammatory myopathies 1.
  • Associated Conditions: Consider autoimmune disorders like Sjögren's syndrome and vitamin B12 deficiency in complex cases 2.
  • Management

  • First-Line Treatments: Corticosteroids and immunosuppressants (e.g., methotrexate, azathioprine) are commonly used, though efficacy is limited 1.
  • Adjunctive Therapies: Physical therapy to maintain muscle function and mobility 1.
  • Drug Repurposing: Exploration of new therapeutic approaches and repurposing existing drugs due to limited treatment options 1.
  • Special Populations

  • Comorbidities: Patients with Sjögren's syndrome and vitamin B12 deficiency may exhibit unique clinical features requiring tailored management 2.
  • Elderly: Focus on symptomatic relief and supportive care due to the elderly predominance of the disease 1.
  • Key Recommendations

  • Confirm Diagnosis with Muscle Biopsy: Essential for distinguishing IBM from other myopathies (Evidence: Moderate 1).
  • Consider Autoimmune Associations: Evaluate for coexisting autoimmune conditions like Sjögren's syndrome and vitamin deficiencies in complex cases (Evidence: Weak 2).
  • Implement Multimodal Therapy: Combine pharmacological treatments with physical therapy to manage symptoms and maintain function (Evidence: Expert opinion 1).
  • References

    1 Balakrishnan A, Aggarwal R, Agarwal V, Gupta L. Inclusion body myositis in the rheumatology clinic. International journal of rheumatic diseases 2020. link 2 Khraishi MM, Jay V, Keystone EC. Inclusion body myositis in association with vitamin B12 deficiency and Sjögren's syndrome. The Journal of rheumatology 1992. link

    Original source

    1. [1]
      Inclusion body myositis in the rheumatology clinic.Balakrishnan A, Aggarwal R, Agarwal V, Gupta L International journal of rheumatic diseases (2020)
    2. [2]
      Inclusion body myositis in association with vitamin B12 deficiency and Sjögren's syndrome.Khraishi MM, Jay V, Keystone EC The Journal of rheumatology (1992)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG